SCHEMBL2433474

SCHEMBL2433474

O=C(O)Cc1ccc2nc(Nc3ccccc3Cl)oc2c1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C1R P00736 6/20 0.52
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
ALDH1A1 P00352 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CXCL8 P10145 3/20 0.51
ITGB1 P05556 5/20 0.47
ITGA4 P13612 5/20 0.47
AKR1B10 O60218 1/20 0.43
UGT1A9 O60656 1/20 0.43
TRPA1 O75762 1/20 0.43
ABCB11 O95342 1/20 0.43
MT-CO2 P00403 1/20 0.43
TTR P02766 1/20 0.43
ALB P02768 1/20 0.43
UGT1A6 P19224 1/20 0.43
UGT1A1 P22309 1/20 0.43
PTGS1 P23219 1/20 0.43
CXCR1 P25024 1/20 0.43
ADRA1A P35348 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14591740 0.88 C1R (0.46) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2432225 0.88 ITGB1 (0.49) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2433731 0.87 ITGB1 (0.57) C1RNPC1RAB9ASMN1; SMN2ITGB1
SCHEMBL2433190 0.87 ITGB1 (0.45) C1RNPC1RAB9AALDH1A1CXCL8
SCHEMBL12327888 0.83 C1R (0.50) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2430157 0.83 PTGS2 (0.52) C1RCXCL8ITGB1ITGA4AKR1B10
SCHEMBL2433688 0.83 ITGB1 (0.57) C1RNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2432841 0.81 ITGB1 (0.49) ITGB1ITGA4
SCHEMBL2432759 0.78 ITGB1 (0.58) ITGB1ITGA4
SCHEMBL2431856 0.78 ITGB1 (0.57) ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 C1R 2051/4885NPC1 1278/4885RAB9A 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.